# Clinical Validation Report of

# COVID-19 Ag Rapid Test Device

**Product name:** COVID-19 Ag Rapid Test Device

Cat# CO-05

**Manufacturer:** Jiangsu Well Biotech Co., Ltd.

## 1. Background information for clinicalevaluation

The SARS-CoV-2 belong to the genus Nestovirus, Coronaviridae, and is divided into threegenera:α,β,andγ.Thegenusαandβareonlypathogenictomammals.COVID-19isanacuterespiratoryinfectiousdiseaseinfectedwithSARS-CoV-2.Currently,the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiologicalinvestigation,theincubationperiodis1to14days,mostly3to7days. Themainmanifestationsincludefever,fatigueanddrycough.Nasalcongestion,runny nose, sore throat, myalgia and diarrhea are found in a fewcases.

The COVID-19 Ag Rapid Test Device developed by Jiangsu Well Biotech Co., Ltd. is a rapid chromatographic immunoassay for the qualitative detection of N antigen to SARS-CoV-2 present in human nasal swabs. The test provides more convenient technical support for timely blocking the spread of the virus.

## 2. Testpurposes

To verify the accuracy and the reliability of the COVID-19 Ag Rapid Test Device produced by Jiangsu Well Biotech Co., Ltd. using the clinical specimen.

## 3. Testdesign

### 3.1 Testplan

COVID-19AgRapidTestDevicesareusedtoconductcomparativeresearch testsonclinicallysuspectedCOVID-19,andtoprovethattheCOVID-19AgRapid Test can be used to detect N antigen in the patient with the SAR-Cov-2 infection with symptom onset of first 7 days. The test results will be compared to reference PCR (BGI Genomics Co., Ltd.)results.

### 3.2 TestingSite

3.2.1 Jiangsu Provincial Center for Disease Control and Prevention

Director: Zhu Fengcai, Operators: Tan zhongmin, Baochangjun

3.2.2 Kangwon National University Hospital (Korea)

Director: Dr. Lee, Operators: SueKim

### 3.3 Samplerequired

The total number of clinical trials of this product is not less than 150 cases. The samples are classified into the potential positive group (symptomatic and asymptomatic) and the negative group (asymptomatic) as per the test results of

the reference PCR. All sample were retrospectively collected either from hospitalized COVID-19 patients or during routine hospital visits.

Enrollment criteria: Samples must be greater than 100uL. If either is the case, sample volume less than 100uL, the sample will be excluded.

The test results of both the Antigen test strip and the reference PCR method shall be compared with statistical analysis.

The reference method is PCR for SARS-CoV-2 nucleic acids in nasal swabs and/or bronchoalveolar lavage fluid (BALF). The name of the PCR test: Real-Time Fluorescent RT-PCR Kit for Detecting SARS-nCoV-2.

The manufacture information of PCR test: BGI Genomics Co.,Ltd.

LOD:100copies/mL

### 3.4 Sample collection, processing andstorage

**Sample collection:** Nasal swab sample has been demonstrated suitable for COVID-19 antigen test strip in the bench study. Collect nasal sample following the procedure described in the instruction for use (IFU).

**Sample processing:** Before testing, slowly return the refrigerated or frozen samples to room temperature and mix them carefully.

**Sample storage:** The collected nasal swab sample should be tested as soon as possible after collection.

## 4. In vitro diagnostic reagents and reference products fortesting

### 4.1 Test in vitro diagnostic reagents

**Name:** COVID-19 Ag Rapid Test

**Cat#:** CO-05,(20tests/kit)

**LOT:** 2006181

**Expiry:** Jun, 2022

**StorageConditions:**Storeinadryplaceat2-30°C,protectedfromlight.Oncethe cassette pouch is open, it should be used within 30 minutes. The cassette will become invalid due to moistureabsorption.

**Manufacture:** Jiangsu Well Biotech Co., Ltd.

### 4.2 Referencereagents

The reference method is PCR, SARS-CoV-2 nucleic acids in nasal swabs from swab

samples. The name of the PCR test: Real-Time Fluorescent RT-PCR Kit for Detecting SARS-nCoV-2.

The manufacture: BGI Genomics Co., Ltd. LOD:100copies/mL

## 5. Experimentmethod

**5.1** Following product instruction, A total of 333 samples including 200 negatives and 133 positives from patients hospitalized or routine visit with symptom onset within 7 days, who were confirmed with PCR referencemethod.

**5.2** Each sample was blind labeled and tested in randomorder.

**5.3** The testing procedure follows below. For details, please refer to the product instruction:

1) Allow the test, the specimen andthe extraction buffer to equilibrate to room temperature (15-30°C) prior to testing.

2) Remove the test device from the sealed foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed immediately after opening the foil pouch.

3) Put the test device on a clean and level surface.

4) Shake the swab specimen in the collectiontube to well mix.

5) Transfer 3 drops (~75μl) of the samplefrom the nozzleto the sample well of the test device and make sure a colored liquid appearing in the detection window in 30 seconds.

6) Start the timer. Read the result at 15~20 minutes.Do not interpret the result after 20 minutes.

**Note:** The test steps need to be completed under protection against infection.

## 6. Statistical methods of statistical analysis of clinical researchdata

### 6.1 Methods evaluating clinicalperformance

Whether various indexes can reach the standards of clinical evaluation shall be judgedbycalculatingtheconsistencypercentageofnegative/positiveandthetotal consistency percentage in the test results of the product tested and the reference product, to validate the accuracy and applicability of the product in clinical applications. The determination results of both products shall be compared. The test results recorded shall be subject to statistical analysis upon completion of determination of all clinical samples, to calculate the consistency percentage of negative/positiveandthetotalconsistencypercentage.Afterwards,equivalenceof both shall be evaluated as per these statisticalindexes.

### 6.2 Statisticalmethod

The products launched on the market shall be subject to comparative study and evaluation.Eachsampleshallbetestedwiththeproductandthe reference PCR product respectively, and then the consistency in statistical results of these two inspection methods shall be compared through Kappainspection.

ThedatashallbesubjectedtoKappainspectionandanalysisandtheKappa coefficient shall be calculated. Favorable consistency can be proven if Kappais > 0.8. The consistency in test results of the product and the reference PCR product are evaluated as per the evaluation standards.

## 7. Criteria of clinicalevaluation

The coincidence rate shall be calculated by comparing with the reference product. The product performance shall meet the following requirements.

**Coincidence rate of negative:** More than 90% of the samples tested should indicate negative results for both the product and the reference PCR product.

**Coincidence rate of positive:** More than 90% of the samples tested should indicate positive results for both the product and the reference PCR product.

## 8. Provisions for amendments to clinicalvalidation

In general, the clinical validation protocol should not be changed. Any modification to the project during the test must be documented and explained. The time, reason for the change, process of the change, and whether there is a record of the change needtobeexplainedindetailanditsimpactontheentireresearchresultexplained.

There was no change in protocol during this clinical evaluation.

## 9. Results and Analysis of ClinicalTests

In total, 200 normal negative and 133 potential positive symptomatic and asymptomatic patient candidates nasal swab samples were used in this clinical evaluation. The samples include different gender and age. Most positive sample tested are in early stage of infection.

The test results are summarized in the table below:

 

Table 1. The result for accuracy

| | | COVID-19 Ag Rapid Test Device | | Total Result |
|---|---|---|---|---|
| | | + | - | |
| PCR | + | 126 | 7 | 133 |
| | - | 0 | 200 | 200 |
| Total Results | | 126 | 207 | 333 |

As summarized in the above table, all 200 negative specimens gave negative results; out of 133 positive specimens, 126 shown antigen positive, The result shows:

Relative sensitivity: 126/133= 94.74% (95%CI89.53%~97.43%)

Relative specificity: 200/200 >99% (95%CI 98.12%~100%)

Overall agreement:
(126+200)/(126+0+7+200)*100%=97.90%(95%CI95.73%~98.98%)

CI: Confidence Interval

Kappa=0.96

Agreement of different Ct value interval was summarized and analyzed, see Table 2.

Table 2.Relation of PPA to Ct values

| Ctvalue interval | PCR | COVID-19 Ag Rapid Test Device | PPA |
|---|---|---|---|
| RdRP Ctvalue＜30 | 108 | 108+ | 100% |
| Ngene Ctvalue＜30 | 108 | 108+ | 100% |
| 30≤RdRP Ct value ＜36 | 20 | 18+ ， 2- | 90% |
| 30≤N gene Ct value ＜36 | 25 | 18+ ， 7- | 72% |

**10. Analysis on consistency in TestResults**

According to the test result, there are 326 samples showing the consistency results for rapid test and RT-PCR. For qualitative rapid test, the result will show positive, negative and invalid, for RT-PCR detection, the Ct value will indicate the result, Ct value>40 means the detection result is negative.

In our validation test, the amountofRdRPCtvaluebelow40is128, the amountofNgeneCtvaluebelow40is133, the amountofbothRdRPandNgeneCtvalueareallbelow40is128.Themedianof RdRP Ct value is 21.82, while the N gene Ctvalue is21.38.

Table 3. The consistency in TestResult

| RdRP Ct value (Total of 128 data below 40) | | | N gene Ct value (Total of 133 data below 40) | | |
|---|---|---|---|---|---|
| Maximum | Minimum | Median | Maximum | Minimum | Median |
| 35.31 | 14.25 | 21.82 | 35.46 | 14.01 | 21.38 |

## 11. Analysis on Inconsistency in Test Results

7 confirmed by PCR positive samples, showed Antigen negative. This may due to the insufficient of sample collected.

Table 4: The Inconsistency in TestResult

| Sample ID | Age | Gender | COVID-19 Ag Test | PCR | |
|---|---|---|---|---|---|
| | | | | RdRP | N gene |
| NS224 | 45 | F | - | 34.17 | 35.46 |
| NS227 | 17 | M | - | 35.12 | 34.21 |
| NS257 | 34 | F | - | >40 | 34.28 |
| NS262 | 39 | F | - | >40 | 34.15 |
| NS304 | 32 | M | - | >40 | 32.29 |
| NS314 | 22 | M | - | >40 | 34.22 |
| NS329 | 42 | M | - | >40 | 34.21 |

## 12. Discussion andConclusions

### 12.1 Discussion

**Results of comparative analysis of the product tested and the reference product:**

Test results of the antigen test and the reference PCR product: both the coincidence rate of negative/positive are larger than 90%, indicating favorable consistency with the reference PCR product. In the analysis results of Kappa inspection, Kappa was proven >0.8, indicating favorable and high consistency of both methods. Both systems were considered equivalent.

### 12.2 Testconclusions

ByanalyzingthetestresultsoftheproducttestedandthePCRreferenceproduct, the consistency percentage of negative/positive is proven high. Moreover, according to the results of statistical analysis, there is no remarkable difference in test results of both, indicating favorable consistency in diagnosis and equivalence of two such systems. Therefore, such product is applicable to qualitative clinical

 

analysis on the SARS-CoV-2 antigen in the human nasal swabs, and can be used for auxiliary diagnosis of those suffering from pneumonia triggered byCOVID-19.

## 13. Quality controlmethods

### 13.1 On-site qualitycontrol

The entire clinical evaluation is conducted under strict operation, and the test content is complete and authentic. All observations and findings in the clinical trialshave been verified and the data are reliable. The conclusions in the clinical trials are derived from the original data.

### 13.2 Quality control of clinical experimentprocess

During the evaluation, quality control was performed daily to ensure that the product was under control. Strict quality control is performed to ensure the quality of the clinical testing.

## 14. Prediction of adverseevents

TheCOVID-19AgRapidTestDevice isaninvitrodiagnostictestandthetestresults areonlyusedforcomparativestudies.Itinvolvespersonalprivacy,doesnotserve as a basis for auxiliary diagnosis, does not bring any risk to thesubject.

## 15. References

1. The "Technical Review Points for the Registration of New Coronavirus Antigen / Antibody Detection Reagents in 2019 (Trial)" issued by the State Drug Administration Medical Device Technical Evaluation Center on February 25,2020,

2. "Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Version 6)" issued by the National Health Committee on February 19,2020.

 

## Annex 1: Package Insert

*Attached*

**Annex 2: The Data of Clinical Sample Tests**

| SampleID | Age | Gender | COVID-19 Ag Test | PCR | | SampleID | Age | Gender | COVID-19 Ag Test | PCR | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | RdRP | N gene | | | | | RdRP | N gene |
| NS1 | 42 | F | - | >40 | >40 | NS101 | 28 | F | - | >40 | >40 |
| NS2 | 39 | M | - | >40 | >40 | NS102 | 29 | M | - | >40 | >40 |
| NS3 | 40 | M | - | >40 | >40 | NS103 | 48 | F | - | >40 | >40 |
| NS4 | 17 | F | - | >40 | >40 | NS104 | 44 | M | - | >40 | >40 |
| NS5 | 26 | M | - | >40 | >40 | NS105 | 61 | F | - | >40 | >40 |
| NS6 | 23 | F | - | >40 | >40 | NS106 | 29 | M | - | >40 | >40 |
| NS7 | 16 | M | - | >40 | >40 | NS107 | 57 | F | - | >40 | >40 |
| NS8 | 43 | F | - | >40 | >40 | NS108 | 32 | M | - | >40 | >40 |
| NS9 | 51 | M | - | >40 | >40 | NS109 | 54 | M | - | >40 | >40 |
| NS10 | 22 | M | - | >40 | >40 | NS110 | 71 | F | - | >40 | >40 |
| NS11 | 45 | F | - | >40 | >40 | NS111 | 28 | F | - | >40 | >40 |
| NS12 | 34 | F | - | >40 | >40 | NS112 | 29 | M | - | >40 | >40 |
| NS13 | 61 | F | - | >40 | >40 | NS113 | 48 | F | - | >40 | >40 |
| NS14 | 54 | M | - | >40 | >40 | NS114 | 44 | M | - | >40 | >40 |
| NS15 | 34 | F | - | >40 | >40 | NS115 | 61 | F | - | >40 | >40 |
| NS16 | 23 | M | - | >40 | >40 | NS116 | 29 | M | - | >40 | >40 |
| NS17 | 22 | M | - | >40 | >40 | NS117 | 57 | F | - | >40 | >40 |
| NS18 | 20 | F | - | >40 | >40 | NS118 | 32 | M | - | >40 | >40 |
| NS19 | 18 | M | - | >40 | >40 | NS119 | 42 | F | - | >40 | >40 |
| NS20 | 16 | F | - | >40 | >40 | NS120 | 45 | F | - | >40 | >40 |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NS21 | 14 | M | - | >40 | >40 | NS121 | 36 | M | - | >40 | >40 |
| NS22 | 19 | F | - | >40 | >40 | NS122 | 15 | F | - | >40 | >40 |
| NS23 | 20 | M | - | >40 | >40 | NS123 | 17 | M | - | >40 | >40 |
| NS24 | 27 | M | - | >40 | >40 | NS124 | 42 | F | - | >40 | >40 |
| NS25 | 26 | F | - | >40 | >40 | NS125 | 45 | F | - | >40 | >40 |
| NS26 | 25 | F | - | >40 | >40 | NS126 | 36 | M | - | >40 | >40 |
| NS27 | 28 | F | - | >40 | >40 | NS127 | 15 | F | - | >40 | >40 |
| NS28 | 29 | M | - | >40 | >40 | NS128 | 17 | M | - | >40 | >40 |
| NS29 | 48 | F | - | >40 | >40 | NS129 | 16 | F | - | >40 | >40 |
| NS30 | 44 | M | - | >40 | >40 | NS130 | 54 | M | - | >40 | >40 |
| NS31 | 61 | F | - | >40 | >40 | NS131 | 43 | F | - | >40 | >40 |
| NS32 | 29 | M | - | >40 | >40 | NS132 | 72 | M | - | >40 | >40 |
| NS33 | 57 | F | - | >40 | >40 | NS133 | 49 | F | - | >40 | >40 |
| NS34 | 32 | M | - | >40 | >40 | NS134 | 42 | F | - | >40 | >40 |
| NS35 | 54 | M | - | >40 | >40 | NS135 | 45 | F | - | >40 | >40 |
| NS36 | 71 | F | - | >40 | >40 | NS136 | 42 | F | - | >40 | >40 |
| NS37 | 34 | M | - | >40 | >40 | NS137 | 45 | F | - | >40 | >40 |
| NS38 | 42 | F | - | >40 | >40 | NS138 | 36 | M | - | >40 | >40 |
| NS39 | 45 | F | - | >40 | >40 | NS139 | 55 | F | - | >40 | >40 |
| NS40 | 36 | M | - | >40 | >40 | NS140 | 17 | M | - | >40 | >40 |
| NS41 | 65 | F | - | >40 | >40 | NS141 | 16 | F | - | >40 | >40 |
| NS42 | 37 | M | - | >40 | >40 | NS142 | 64 | M | - | >40 | >40 |
| NS43 | 56 | F | - | >40 | >40 | NS143 | 53 | F | - | >40 | >40 |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NS44 | 44 | M | - | >40 | >40 | NS144 | 12 | M | - | >40 | >40 |
| NS45 | 53 | F | - | >40 | >40 | NS145 | 42 | F | - | >40 | >40 |
| NS46 | 22 | M | - | >40 | >40 | NS146 | 45 | F | - | >40 | >40 |
| NS47 | 19 | F | - | >40 | >40 | NS147 | 36 | M | - | >40 | >40 |
| NS48 | 28 | F | - | >40 | >40 | NS148 | 42 | F | - | >40 | >40 |
| NS49 | 29 | M | - | >40 | >40 | NS149 | 45 | F | - | >40 | >40 |
| NS50 | 48 | F | - | >40 | >40 | NS150 | 36 | M | - | >40 | >40 |
| NS51 | 44 | M | - | >40 | >40 | NS151 | 15 | F | - | >40 | >40 |
| NS52 | 61 | F | - | >40 | >40 | NS152 | 17 | M | - | >40 | >40 |
| NS53 | 29 | M | - | >40 | >40 | NS153 | 16 | F | - | >40 | >40 |
| NS54 | 57 | F | - | >40 | >40 | NS154 | 14 | M | - | >40 | >40 |
| NS55 | 32 | M | - | >40 | >40 | NS155 | 13 | F | - | >40 | >40 |
| NS56 | 54 | M | - | >40 | >40 | NS156 | 12 | M | - | >40 | >40 |
| NS57 | 71 | F | - | >40 | >40 | NS157 | 42 | F | - | >40 | >40 |
| NS58 | 42 | F | - | >40 | >40 | NS158 | 42 | F | - | >40 | >40 |
| NS59 | 45 | F | - | >40 | >40 | NS159 | 46 | F | - | >40 | >40 |
| NS60 | 36 | M | - | >40 | >40 | NS160 | 36 | M | - | >40 | >40 |
| NS61 | 15 | F | - | >40 | >40 | NS161 | 54 | F | - | >40 | >40 |
| NS62 | 17 | M | - | >40 | >40 | NS162 | 23 | M | - | >40 | >40 |
| NS63 | 63 | F | - | >40 | >40 | NS163 | 16 | F | - | >40 | >40 |
| NS64 | 34 | M | - | >40 | >40 | NS164 | 34 | M | - | >40 | >40 |
| NS65 | 23 | F | - | >40 | >40 | NS165 | 53 | F | - | >40 | >40 |
| NS66 | 22 | M | - | >40 | >40 | NS166 | 34 | M | - | >40 | >40 |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NS67 | 19 | F | - | >40 | >40 | NS167 | 42 | F | - | >40 | >40 |
| NS68 | 42 | F | - | >40 | >40 | NS168 | 42 | F | - | >40 | >40 |
| NS69 | 45 | F | - | >40 | >40 | NS169 | 45 | F | - | >40 | >40 |
| NS70 | 36 | M | - | >40 | >40 | NS170 | 36 | M | - | >40 | >40 |
| NS71 | 15 | F | - | >40 | >40 | NS171 | 35 | F | - | >40 | >40 |
| NS72 | 23 | M | - | >40 | >40 | NS172 | 67 | M | - | >40 | >40 |
| NS73 | 32 | F | - | >40 | >40 | NS173 | 66 | F | - | >40 | >40 |
| NS74 | 54 | M | - | >40 | >40 | NS174 | 44 | M | - | >40 | >40 |
| NS75 | 53 | F | - | >40 | >40 | NS175 | 63 | F | - | >40 | >40 |
| NS76 | 32 | M | - | >40 | >40 | NS176 | 22 | M | - | >40 | >40 |
| NS77 | 19 | F | - | >40 | >40 | NS177 | 42 | F | - | >40 | >40 |
| NS78 | 42 | F | - | >40 | >40 | NS178 | 46 | F | - | >40 | >40 |
| NS79 | 45 | F | - | >40 | >40 | NS179 | 37 | M | - | >40 | >40 |
| NS80 | 36 | M | - | >40 | >40 | NS180 | 18 | F | - | >40 | >40 |
| NS81 | 15 | F | - | >40 | >40 | NS181 | 25 | M | - | >40 | >40 |
| NS82 | 65 | M | - | >40 | >40 | NS182 | 16 | F | - | >40 | >40 |
| NS83 | 46 | F | - | >40 | >40 | NS183 | 45 | M | - | >40 | >40 |
| NS84 | 34 | M | - | >40 | >40 | NS184 | 43 | F | - | >40 | >40 |
| NS85 | 53 | F | - | >40 | >40 | NS185 | 65 | M | - | >40 | >40 |
| NS86 | 72 | M | - | >40 | >40 | NS186 | 42 | F | - | >40 | >40 |
| NS87 | 19 | F | - | >40 | >40 | NS187 | 45 | F | - | >40 | >40 |
| NS88 | 42 | F | - | >40 | >40 | NS188 | 36 | M | - | >40 | >40 |
| NS89 | 45 | F | - | >40 | >40 | NS189 | 15 | F | - | >40 | >40 |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NS90 | 37 | M | - | >40 | >40 | NS190 | 17 | M | - | >40 | >40 |
| NS91 | 25 | F | - | >40 | >40 | NS191 | 46 | F | - | >40 | >40 |
| NS92 | 57 | M | - | >40 | >40 | NS192 | 14 | M | - | >40 | >40 |
| NS93 | 36 | F | - | >40 | >40 | NS193 | 63 | F | - | >40 | >40 |
| NS94 | 56 | M | - | >40 | >40 | NS194 | 29 | M | - | >40 | >40 |
| NS95 | 53 | F | - | >40 | >40 | NS195 | 42 | F | - | >40 | >40 |
| NS96 | 32 | M | - | >40 | >40 | NS196 | 45 | F | - | >40 | >40 |
| NS97 | 19 | F | - | >40 | >40 | NS197 | 36 | M | - | >40 | >40 |
| NS98 | 42 | F | - | >40 | >40 | NS198 | 35 | F | - | >40 | >40 |
| NS99 | 45 | F | - | >40 | >40 | NS199 | 57 | M | - | >40 | >40 |
| NS100 | 36 | M | - | >40 | >40 | NS200 | 26 | F | - | >40 | >40 |
| NS201 | 47 | M | + | 16.29 | 15.96 | NS219 | 57 | F | + | 26.2 | 25.94 |
| NS202 | 46 | F | + | 14.42 | 14.01 | NS220 | 32 | M | + | 30.84 | 30.22 |
| NS203 | 34 | M | + | 27.24 | 27.78 | NS221 | 54 | M | + | 27.18 | 27.65 |
| NS204 | 23 | F | + | 31.24 | 30.93 | NS222 | 71 | F | + | 20.14 | 21.32 |
| NS205 | 52 | M | + | 14.65 | 14.73 | NS223 | 42 | F | + | 25.84 | 26.12 |
| NS206 | 28 | F | + | 31.76 | 31.44 | NS224 | 45 | F | - | 34.17 | 35.46 |
| NS207 | 42 | F | + | 22.90 | 23.45 | NS225 | 36 | M | + | 25.68 | 25.68 |
| NS208 | 45 | F | + | 22.65 | 23.10 | NS226 | 35 | F | + | 20.14 | 19.74 |
| NS209 | 36 | M | + | 22.94 | 22.71 | NS227 | 17 | M | - | 35.12 | 34.21 |
| NS210 | 17 | M | + | 31.85 | 31.55 | NS228 | 56 | F | + | 27.18 | 27.45 |
| NS211 | 57 | F | + | 34.86 | 33.76 | NS229 | 77 | M | + | 23.49 | 23.42 |
| NS212 | 32 | M | + | 14.25 | 14.39 | NS230 | 16 | F | + | 22.87 | 23.09 |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NS213 | 54 | M | + | 31.76 | 31.44 | NS231 | 34 | M | + | 20.14 | 19.74 |
| NS214 | 71 | F | + | 24.09 | 24.57 | NS232 | 33 | F | + | 19.34 | 19.34 |
| NS215 | 42 | F | + | 27.34 | 26.79 | NS233 | 42 | M | + | 30.21 | 30.42 |
| NS216 | 45 | F | + | 19.24 | 19.43 | NS234 | 19 | F | + | 24.64 | 24.15 |
| NS217 | 36 | M | + | 27.18 | 26.91 | NS235 | 42 | F | + | 18.43 | 18.25 |
| NS218 | 15 | F | + | 19.39 | 19.51 | NS236 | 33 | F | + | 19.47 | 19.29 |
| NS237 | 54 | M | + | 31.76 | 31.44 | NS254 | 55 | M | + | 20.14 | 19.74 |
| NS238 | 71 | F | + | 24.09 | 24.57 | NS255 | 53 | F | + | 19.34 | 19.34 |
| NS239 | 42 | F | + | 27.34 | 26.79 | NS256 | 24 | M | + | 33.01 | 33.21 |
| NS240 | 45 | F | + | 19.24 | 19.43 | NS257 | 34 | F | - | >40 | 34.28 |
| NS241 | 36 | M | + | 27.18 | 26.91 | NS258 | 45 | F | + | 18.43 | 18.25 |
| NS242 | 54 | M | + | 31.76 | 31.44 | NS259 | 64 | M | + | 20.14 | 19.74 |
| NS243 | 71 | F | + | 24.09 | 24.57 | NS260 | 43 | F | + | 19.34 | 19.34 |
| NS244 | 42 | M | + | 27.34 | 26.79 | NS261 | 52 | M | + | 23.21 | 23.16 |
| NS245 | 45 | F | + | 19.24 | 19.43 | NS262 | 39 | F | - | >40 | 34.15 |
| NS246 | 36 | M | + | 27.18 | 26.91 | NS263 | 62 | F | + | 18.43 | 18.25 |
| NS247 | 54 | M | + | 31.76 | 31.44 | NS264 | 74 | M | + | 20.14 | 19.74 |
| NS248 | 71 | M | + | 24.09 | 24.57 | NS265 | 56 | F | + | 19.34 | 19.34 |
| NS249 | 42 | F | + | 27.34 | 26.79 | NS266 | 76 | M | + | 23.91 | 24.21 |
| NS250 | 45 | F | + | 19.24 | 19.43 | NS267 | 59 | F | + | 24.64 | 24.15 |
| NS251 | 36 | M | + | 27.18 | 26.91 | NS268 | 46 | F | + | 18.43 | 18.25 |
| NS252 | 54 | M | + | 31.76 | 31.44 | NS269 | 64 | M | + | 20.14 | 19.74 |
| NS253 | 71 | F | + | 24.09 | 24.57 | NS270 | 63 | F | + | 19.34 | 19.34 |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NS271 | 42 | F | + | 27.34 | 26.79 | NS294 | 22 | M | + | 35.31 | 34.25 |
| NS272 | 45 | F | + | 19.24 | 19.43 | NS295 | 18 | F | + | 24.64 | 24.15 |
| NS273 | 36 | M | + | 27.18 | 26.91 | NS296 | 43 | F | + | 18.43 | 18.25 |
| NS274 | 54 | M | + | 31.76 | 31.44 | NS297 | 24 | M | + | 20.14 | 19.74 |
| NS275 | 72 | F | + | 24.09 | 24.57 | NS298 | 43 | F | + | 19.34 | 19.34 |
| NS276 | 43 | F | + | 27.34 | 26.79 | NS299 | 22 | M | + | 18.23 | 18.25 |
| NS277 | 45 | M | + | 19.24 | 19.43 | NS300 | 59 | M | + | 24.64 | 24.15 |
| NS278 | 46 | M | + | 27.18 | 26.91 | NS301 | 42 | F | + | 18.43 | 18.25 |
| NS279 | 54 | M | + | 31.76 | 31.44 | NS302 | 54 | M | + | 20.14 | 19.74 |
| NS280 | 71 | F | + | 24.09 | 24.57 | NS303 | 53 | F | + | 19.34 | 19.34 |
| NS281 | 45 | M | + | 27.34 | 26.79 | NS304 | 32 | M | - | >40 | 32.29 |
| NS282 | 43 | F | + | 19.24 | 19.43 | NS305 | 69 | F | + | 24.64 | 24.15 |
| NS283 | 36 | M | + | 27.18 | 26.91 | NS306 | 42 | F | + | 18.43 | 18.25 |
| NS284 | 54 | M | + | 31.76 | 31.44 | NS307 | 64 | M | + | 20.14 | 19.74 |
| NS285 | 54 | F | + | 24.09 | 24.57 | NS308 | 43 | F | + | 19.34 | 19.34 |
| NS286 | 40 | F | + | 27.34 | 26.79 | NS309 | 32 | M | + | 23.42 | 22.21 |
| NS287 | 42 | F | + | 19.24 | 19.43 | NS310 | 59 | F | + | 24.64 | 24.15 |
| NS288 | 36 | M | + | 27.18 | 26.91 | NS311 | 42 | F | + | 18.43 | 18.25 |
| NS289 | 54 | M | + | 31.76 | 31.44 | NS312 | 24 | M | + | 20.14 | 19.74 |
| NS290 | 71 | M | + | 24.09 | 24.57 | NS313 | 53 | F | + | 19.34 | 19.34 |
| NS291 | 42 | F | + | 27.34 | 26.79 | NS314 | 22 | M | - | >40 | 34.22 |
| NS292 | 45 | F | + | 19.24 | 19.43 | NS315 | 49 | F | + | 24.64 | 24.15 |
| NS293 | 36 | M | + | 27.18 | 26.91 | NS316 | 45 | F | + | 18.43 | 18.25 |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NS317 | 54 | M | + | 31.76 | 31.44 | NS327 | 64 | M | + | 20.14 | 19.74 |
| NS318 | 71 | F | + | 24.09 | 24.57 | NS328 | 63 | F | + | 19.34 | 19.34 |
| NS319 | 42 | F | + | 27.34 | 26.79 | NS329 | 42 | M | - | >40 | 34.21 |
| NS320 | 45 | F | + | 19.24 | 19.43 | NS330 | 29 | F | + | 24.64 | 24.15 |
| NS321 | 36 | M | + | 27.18 | 26.91 | NS331 | 46 | M | + | 18.43 | 18.25 |
| NS322 | 15 | F | + | 19.39 | 19.51 | NS332 | 72 | F | + | 24.09 | 24.57 |
| NS323 | 71 | F | + | 24.09 | 24.57 | NS333 | 46 | F | + | 27.34 | 26.79 |
| NS324 | 42 | F | + | 27.34 | 26.79 | / | / | / | / | / | / |
| NS325 | 45 | F | + | 19.24 | 19.43 | / | / | / | / | / | / |
| NS326 | 36 | M | + | 27.18 | 26.91 | / | / | / | / | / | / |